DK1437353T3 - Alkyletherderivater eller deres salte - Google Patents

Alkyletherderivater eller deres salte

Info

Publication number
DK1437353T3
DK1437353T3 DK02777882T DK02777882T DK1437353T3 DK 1437353 T3 DK1437353 T3 DK 1437353T3 DK 02777882 T DK02777882 T DK 02777882T DK 02777882 T DK02777882 T DK 02777882T DK 1437353 T3 DK1437353 T3 DK 1437353T3
Authority
DK
Denmark
Prior art keywords
alkyl ether
ether derivatives
salts
new
optionally substituted
Prior art date
Application number
DK02777882T
Other languages
Danish (da)
English (en)
Inventor
Akihito Saitoh
Noboru Iwakami
Tamotsu Takamatsu
Original Assignee
Toyama Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toyama Chemical Co Ltd filed Critical Toyama Chemical Co Ltd
Application granted granted Critical
Publication of DK1437353T3 publication Critical patent/DK1437353T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
DK02777882T 2001-10-19 2002-10-18 Alkyletherderivater eller deres salte DK1437353T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001321381 2001-10-19
PCT/JP2002/010827 WO2003035647A1 (fr) 2001-10-19 2002-10-18 Derives ou sels d'ether d'alkyle

Publications (1)

Publication Number Publication Date
DK1437353T3 true DK1437353T3 (da) 2007-08-06

Family

ID=19138603

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02777882T DK1437353T3 (da) 2001-10-19 2002-10-18 Alkyletherderivater eller deres salte

Country Status (23)

Country Link
US (4) US7087594B2 (pt)
EP (1) EP1437353B1 (pt)
JP (1) JP4398247B2 (pt)
KR (1) KR100956990B1 (pt)
CN (2) CN100500662C (pt)
AT (1) ATE364604T1 (pt)
AU (1) AU2002344107B2 (pt)
BR (1) BRPI0213393B8 (pt)
CA (1) CA2464358C (pt)
CY (1) CY1106714T1 (pt)
DE (1) DE60220694T2 (pt)
DK (1) DK1437353T3 (pt)
ES (1) ES2287324T3 (pt)
HU (1) HU230407B1 (pt)
IL (2) IL161308A0 (pt)
MX (1) MXPA04003541A (pt)
NO (1) NO325780B1 (pt)
NZ (1) NZ532328A (pt)
PL (2) PL215264B1 (pt)
PT (1) PT1437353E (pt)
RO (1) RO122203B1 (pt)
WO (1) WO2003035647A1 (pt)
ZA (1) ZA200402806B (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1437353T3 (da) * 2001-10-19 2007-08-06 Toyama Chemical Co Ltd Alkyletherderivater eller deres salte
DK2389937T3 (en) * 2002-06-14 2018-11-12 Toyama Chemical Co Ltd Medical composition to improve brain function
US20060205709A1 (en) * 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
AU2011204959B2 (en) * 2005-03-28 2012-04-12 Toyama Chemical Co., Ltd. Process for production of 1-(3-(2-(1-benzothiophen-5-YL)- ethoxy)propyl)azetidin-3-ol or salts thereof
EP1864978A4 (en) * 2005-03-28 2009-07-01 Toyama Chemical Co Ltd PROCESS FOR PRODUCING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) -ETHOXY) PROPYL) AZETIDIN-3-OL OR ITS SALTS
JP4902247B2 (ja) * 2005-04-08 2012-03-21 富山化学工業株式会社 2−(1−ベンゾチオフェン−5−イル)エタノールの新規製造法およびその中間体
JP2006328058A (ja) * 2005-04-27 2006-12-07 Toyama Chem Co Ltd 2−(1−ベンゾチオフェン−5−イル)エタノールの新規製造法およびその中間体
US20090093453A1 (en) * 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
DK2048145T3 (da) * 2006-08-04 2011-04-04 Toyama Chemical Co Ltd Forstærker af aktiviteten af proteinkinase C indeholdende alkyletherderivat eller et salt deraf
MX2010012787A (es) * 2008-05-28 2011-02-24 Toyama Chemical Co Ltd Nuevo derivado de oxido de benzotiofeno y sal del mismo.
CA2865380C (en) 2012-02-22 2019-10-29 Toyama Chemical Co., Ltd. Solid pharmaceutical composition containing 1-(3-(2-(1-benzothiophen-5-yl)ethoxy)propyl)azetidin-3-ol or salt thereof
CN106061478B (zh) 2014-01-31 2019-04-30 富士胶片富山化学株式会社 含有烷基醚衍生物或其盐的神经损伤后的康复效果促进剂
JP6761413B2 (ja) * 2015-06-11 2020-09-23 富士フイルム富山化学株式会社 シグマ受容体結合剤
CN108366989B (zh) 2015-12-25 2020-11-03 富士胶片富山化学株式会社 含有1-(3-(2-(1-苯并噻吩-5-基-)乙氧基)丙基)氮杂环丁-3-醇或其盐的片剂
JP7057287B2 (ja) 2016-12-28 2022-04-19 富士フイルム富山化学株式会社 医薬組成物
JP7057286B2 (ja) 2016-12-28 2022-04-19 富士フイルム富山化学株式会社 医薬組成物
WO2018124281A1 (ja) 2016-12-28 2018-07-05 富山化学工業株式会社 外用組成物
US11234962B2 (en) 2016-12-28 2022-02-01 Fujifilm Toyama Chemical Co., Ltd. Pharmaceutical composition and method of manufacturing the same
SG11201911519UA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd AGENT FOR REDUCING AMOUNT OF AMYLOID ß PROTEIN
US11660287B2 (en) 2017-06-02 2023-05-30 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating spinocerebellar ataxia
AU2018277982B2 (en) 2017-06-02 2021-04-08 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating tauopathy
JPWO2018221728A1 (ja) 2017-06-02 2020-04-02 富士フイルム富山化学株式会社 アルツハイマー型認知症予防または治療剤
JP7282028B2 (ja) 2017-06-02 2023-05-26 富士フイルム富山化学株式会社 脳萎縮予防または治療剤
US11548878B2 (en) 2017-10-30 2023-01-10 Fujifilm Toyama Chemical Co., Ltd. Emopamil binding protein binding agent and use thereof
CN114853619B (zh) * 2022-05-19 2024-05-10 神隆医药(常熟)有限公司 一种适于工业化生产的n-甲基酪胺盐酸盐的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01156973A (ja) 1987-09-04 1989-06-20 Tanabe Seiyaku Co Ltd ベンゾフラン誘導体
JP2887492B2 (ja) 1990-02-05 1999-04-26 富山化学工業株式会社 1,2―エタンジオール誘導体およびその塩
JP3044055B2 (ja) 1990-08-09 2000-05-22 富山化学工業株式会社 1,2―エタンジオール誘導体およびその塩
DK74693D0 (da) 1993-06-23 1993-06-23 Novo Nordisk As Novel heterocyclic chemistry
JP3232830B2 (ja) 1993-11-30 2001-11-26 三菱電機株式会社 フレキシブルディスク装置のキャリッジ機構
JPH08268883A (ja) 1994-10-25 1996-10-15 Toyama Chem Co Ltd 1−フェニル−1,2−エタンジオール誘導体またはそ の塩を含有する神経成長因子の作用増強剤
WO1996012717A1 (fr) * 1994-10-25 1996-05-02 Toyama Chemical Co., Ltd. Potentialisateur de l'activite du facteur de croissance nerveuse contenant un derive de 1,2-ethanediol ou un sel de celui-ci
AU710984B2 (en) 1995-08-11 1999-10-07 Pfizer Inc. (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin -1-yl)-1-propanolmethanesulfonate trihydrate
AU7001796A (en) 1995-09-22 1997-04-09 Yoshitomi Pharmaceutical Industries, Ltd. Benzoic acid compounds and medicinal use thereof
DE19605610A1 (de) 1996-02-15 1997-08-21 Hoechst Ag Substituierte Thiophenylalkenylcarbonsäureguanidide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU1672597A (en) 1996-02-20 1997-09-10 Toyama Chemical Co. Ltd. Cerebral function ameliorant containing 1,2-ethanediol derivatives or salts thereof
JP4549452B2 (ja) 1997-12-12 2010-09-22 富山化学工業株式会社 アルキルエーテル誘導体またはその塩並びにそれらを含有するカルシウム拮抗剤
WO1999031056A1 (fr) * 1997-12-12 1999-06-24 Toyama Chemical Co., Ltd. Derives d'ether alcoylique ou leurs sels, et antagonistes du calcium les contenant
KR100641352B1 (ko) 1999-06-11 2006-11-02 토야마 케미칼 컴퍼니 리미티드 N-알콕시알킬-n,n-디알킬아민 유도체 또는 그 염, 및이를 함유하는 신경퇴행성질환 치료제
DK1437353T3 (da) 2001-10-19 2007-08-06 Toyama Chemical Co Ltd Alkyletherderivater eller deres salte
DK2389937T3 (en) 2002-06-14 2018-11-12 Toyama Chemical Co Ltd Medical composition to improve brain function
US20060205709A1 (en) 2003-04-17 2006-09-14 Toyama Chemical Co., Ltd. Preventive/remedy for retinal nerve diseases containing alkyl ether derivatives or salts thereof
EP1864978A4 (en) 2005-03-28 2009-07-01 Toyama Chemical Co Ltd PROCESS FOR PRODUCING 1- (3- (2- (1-BENZOTHIOPHEN-5-YL) -ETHOXY) PROPYL) AZETIDIN-3-OL OR ITS SALTS
US20090093453A1 (en) 2006-04-26 2009-04-09 Toyama Chemical Co., Ltd Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
US8119625B2 (en) 2006-04-26 2012-02-21 Toyama Chemical Co., Ltd. Neurogenesis inducer or neuropathy therapeutic agent comprising alkyl ether derivative or salt thereof
DK2048145T3 (da) 2006-08-04 2011-04-04 Toyama Chemical Co Ltd Forstærker af aktiviteten af proteinkinase C indeholdende alkyletherderivat eller et salt deraf
MX2010012787A (es) 2008-05-28 2011-02-24 Toyama Chemical Co Ltd Nuevo derivado de oxido de benzotiofeno y sal del mismo.

Also Published As

Publication number Publication date
NZ532328A (en) 2005-07-29
BR0213393A (pt) 2005-01-11
MXPA04003541A (es) 2004-07-22
HU230407B1 (hu) 2016-04-28
CN1571786A (zh) 2005-01-26
NO20041531L (no) 2004-04-15
DE60220694D1 (de) 2007-07-26
AU2002344107B2 (en) 2007-11-01
USRE43676E1 (en) 2012-09-18
EP1437353B1 (en) 2007-06-13
DE60220694T2 (de) 2008-02-07
US7087594B2 (en) 2006-08-08
IL161308A0 (en) 2004-09-27
US8129535B2 (en) 2012-03-06
US20050070521A1 (en) 2005-03-31
CA2464358C (en) 2011-05-24
WO2003035647A1 (fr) 2003-05-01
KR20040050919A (ko) 2004-06-17
IL161308A (en) 2011-06-30
JP4398247B2 (ja) 2010-01-13
KR100956990B1 (ko) 2010-05-11
CN101643470A (zh) 2010-02-10
HUP0500017A2 (hu) 2005-04-28
CN101643470B (zh) 2012-08-01
PT1437353E (pt) 2007-08-28
NO325780B1 (no) 2008-07-14
EP1437353A1 (en) 2004-07-14
CN100500662C (zh) 2009-06-17
BRPI0213393B1 (pt) 2018-12-04
HUP0500017A3 (en) 2011-07-28
ATE364604T1 (de) 2007-07-15
PL369601A1 (en) 2005-05-02
CY1106714T1 (el) 2012-05-23
PL215264B1 (pl) 2013-11-29
US20090111992A1 (en) 2009-04-30
RO122203B1 (ro) 2009-02-27
US7468443B2 (en) 2008-12-23
EP1437353A4 (en) 2005-01-19
CA2464358A1 (en) 2003-05-01
PL402986A1 (pl) 2013-04-29
ES2287324T3 (es) 2007-12-16
US20060194781A1 (en) 2006-08-31
BRPI0213393B8 (pt) 2021-05-25
PL217872B1 (pl) 2014-08-29
ZA200402806B (en) 2005-06-29
JPWO2003035647A1 (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
DK1437353T3 (da) Alkyletherderivater eller deres salte
BRPI0509364B8 (pt) derivados de tetraidroquinolina, composição farmacêutica que os compreende e um processo por preparar os referidos derivados
BR9910467A (pt) Composto derivado de amida, processo para a preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
KR890008137A (ko) 3-[4(1-치환된-4-피페라지닐)부틸]-4-티아졸리디노 이의 제조방법 및 약제로서의 이의 용도
ES2182852T3 (es) Derivados de prolinamida.
BR0116450A (pt) Composto, processos para a preparação de um carbamato, e para produzir um sal, composição farmacêutica, uso de um composto ou de uma composição farmacêutica, e, produto de combinação
BR0212458A (pt) Composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, pró-droga, método para a produção de um efeito antibacteriano em um animal de sangue quente, uso de um composto ou sal farmaceuticamente aceitável, ou um éster hidrolizável in vivo deste, composição farmacêutica, e, processo para a preparação de um composto ou sais farmaceuticamente aceitável, ou ésteres hidrolizáveis in vivo deste
MXPA04003610A (es) Analogos de himbacina como antagonistas del receptor de trombina.
ATE540938T1 (de) Neue benzoxazinonderivate als langwirksame betamimetika zur behandlung von atemwegserkrankungen
BRPI0606110A2 (pt) compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores
DK1018511T3 (da) Isochromanforbindelser og fremgangsmåde til deres fremstilling
SG11201804100UA (en) Pharmaceutical composition comprising a potent inhibitor of urat1
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
JP2004513063A5 (pt)
EP1813270A4 (en) PROTEIN INHIBITORS OF THE HSP90 FAMILY
JP2002030084A5 (pt)
NO20000722L (no) 2-(4-aryl eller heteroaryl-piperazin-1-ylmetyl)-1H- indolderivater
DE60032016D1 (de) Zyklische aminverbindungen als ccr5-rezeptor antagonisten
ATE402151T1 (de) 2-(arylphenyl)amino-imidazolin-derivate
ATE489394T1 (de) Ä(4-oxo-4h-chromen-3-yl)-hydroxymethylü- oder ä(4-oxo-4h-chromen-3-yl)-methylü- phosphonsäurederivate
BRPI0409088A (pt) composições farmacêuticas para administração intranasal de ácido [2-(8,9-dioxo-2,6-diazabiciclo [5.2.0]non-1(7)-en-2-il)alquil]-fosfÈnico e derivados e métodos de uso dos mesmos
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
ATE402179T1 (de) Indolderivate und deren verwendung in medikamenten
BR9814961A (pt) Composto ou um sal ou derivado deste farmacologicamente aceitáveis, e, medicamentos antiinflamatório, para prevenção ou tratamento de reumatismo crÈnico, e para prevenção ou tratamento de osteoartrite
ATE469129T1 (de) N-ä(1,5-diphenyl-1h-pyrazol-3- yl)methylüsulfonamid-derivate antagonisten der cb1 rezeptoren der cannabinoide